| scholarly article | Q13442814 |
| P50 | author | Beverley Adams-Huet | Q92029130 |
| Gloria L. Vega | Q124654902 | ||
| P2093 | author name string | Philip Raskin | |
| Robert D Toto | |||
| Uzma F Mehdi | |||
| P2860 | cites work | Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes | Q28188162 |
| The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure<SUBTITLE>The JNC 7 Report</SUBTITLE> | Q28204197 | ||
| The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators | Q28372091 | ||
| Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy | Q29615215 | ||
| The EPHESUS trial: eplerenone in patients with heart failure due to systolic dysfunction complicating acute myocardial infarction. Eplerenone Post-AMI Heart Failure Efficacy and Survival Study | Q34086740 | ||
| Aldosterone receptor blockade and the role of eplerenone: evolving perspectives | Q35296993 | ||
| Prognosis in diabetic nephropathy | Q35713517 | ||
| Aldosterone in the development and progression of renal injury | Q35807297 | ||
| The mineralocorticoid receptor: insights into its molecular and (patho)physiological biology | Q36238325 | ||
| Proteinuria reduction: mandatory consideration or option when selecting an antihypertensive agent? | Q36255432 | ||
| Aldosterone antagonism in chronic kidney disease | Q36910424 | ||
| Change in proteinuria after adding aldosterone blockers to ACE inhibitors or angiotensin receptor blockers in CKD: a systematic review | Q37063760 | ||
| Aldosterone and glomerular podocyte injury | Q37101361 | ||
| Risk scores for predicting outcomes in patients with type 2 diabetes and nephropathy: the RENAAL study | Q40182836 | ||
| Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: lessons from RENAAL. | Q40509707 | ||
| Development and progression of nephropathy in type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS 64). | Q44242786 | ||
| Effectiveness of aldosterone blockade in patients with diabetic nephropathy | Q44269017 | ||
| Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes | Q44295713 | ||
| Aldosterone antagonism ameliorates proteinuria and nephrosclerosis independent of glomerular dynamics in L-NAME/SHR model | Q44805795 | ||
| Effect of aldosterone on renal transforming growth factor-beta | Q44886467 | ||
| The JNC 7 approach compared to conventional treatment in diabetic patients with hypertension: a double-blind trial of initial monotherapy vs. combination therapy | Q45016829 | ||
| Diabetic nephropathy: Linking histology, cell biology, and genetics | Q46130537 | ||
| Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial. | Q46426098 | ||
| Impact of achieved blood pressure on cardiovascular outcomes in the Irbesartan Diabetic Nephropathy Trial | Q46522431 | ||
| Independent and additive impact of blood pressure control and angiotensin II receptor blockade on renal outcomes in the irbesartan diabetic nephropathy trial: clinical implications and limitations | Q46667923 | ||
| Beneficial effects of adding spironolactone to recommended antihypertensive treatment in diabetic nephropathy: a randomized, double-masked, cross-over study | Q46670272 | ||
| Mineralocorticoid blockade reduces vascular injury in stroke-prone hypertensive rats | Q48546780 | ||
| Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy | Q57704237 | ||
| Beneficial impact of spironolactone on nephrotic range albuminuria in diabetic nephropathy | Q59489249 | ||
| Renoprotective effects of angiotensin II receptor blockade in type 1 diabetic patients with diabetic nephropathy | Q59489271 | ||
| Reduction in albuminuria predicts a beneficial effect on diminishing the progression of human diabetic nephropathy during antihypertensive treatment | Q60218011 | ||
| Impact of Arterial Blood Pressure and Albuminuria on the Progression of Diabetic Nephropathy in IDDM Patients | Q60218014 | ||
| A method for estimating nitrogen intake of patients with chronic renal failure | Q70076091 | ||
| The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group | Q70513402 | ||
| Effect of intensive blood pressure control on the course of type 1 diabetic nephropathy. Collaborative Study Group | Q73181267 | ||
| Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. The GISEN Group (Gruppo Italiano di Studi Epidemiologici in Nefrologia) | Q73499190 | ||
| Role of aldosterone in renal vascular injury in stroke-prone hypertensive rats | Q77945596 | ||
| Spironolactone in type 2 diabetic nephropathy: Effects on proteinuria, blood pressure and renal function | Q79279587 | ||
| Longitudinal follow-up and outcomes among a population with chronic kidney disease in a large managed care organization | Q79811373 | ||
| K/DOQI clinical practice guidelines on hypertension and antihypertensive agents in chronic kidney disease | Q80010742 | ||
| Double-blind, placebo-controlled study on the effect of the aldosterone receptor antagonist spironolactone in patients who have persistent proteinuria and are on long-term angiotensin-converting enzyme inhibitor therapy, with or without an angiotens | Q80796915 | ||
| Selective aldosterone blockade with eplerenone reduces albuminuria in patients with type 2 diabetes | Q80797117 | ||
| P433 | issue | 12 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | mineralocorticoid | Q422519 |
| diabetic nephropathy | Q1129105 | ||
| P304 | page(s) | 2641-50 | |
| P577 | publication date | 2009-12-01 | |
| P1433 | published in | Journal of the American Society of Nephrology | Q17123893 |
| P1476 | title | Addition of angiotensin receptor blockade or mineralocorticoid antagonism to maximal angiotensin-converting enzyme inhibition in diabetic nephropathy | |
| P478 | volume | 20 |
| Q48745295 | A complex interplay of factors causes diabetic nephropathy |
| Q35896647 | A method for isolation and identification of urinary biomarkers in patients with diabetic nephropathy |
| Q39290260 | A review of chemical therapies for treating diabetic hypertension |
| Q47122991 | A systematic review and meta-analysis of the impact of mineralocorticoid receptor antagonists on glucose homeostasis |
| Q28542507 | AS101 prevents diabetic nephropathy progression and mesangial cell dysfunction: regulation of the AKT downstream pathway |
| Q58134776 | Acid retention accompanies reduced GFR in humans and increases plasma levels of endothelin and aldosterone |
| Q42878981 | Acid retention during kidney failure induces endothelin and aldosterone production which lead to progressive GFR decline, a situation ameliorated by alkali diet. |
| Q37763640 | Activation of the aldosterone/mineralocorticoid receptor system in chronic kidney disease and metabolic syndrome |
| Q34491934 | Advances in treatment of hyperkalemia in chronic kidney disease |
| Q38139240 | Aggressive blood pressure reduction and renin-angiotensin system blockade in chronic kidney disease: time for re-evaluation? |
| Q35682234 | Albuminuria is Not an Appropriate Therapeutic Target in Patients with CKD: The Con View |
| Q36836343 | Aldosterone Predicts Cardiovascular, Renal, and Metabolic Disease in the General Community: A 4-Year Follow-Up |
| Q35115799 | Aldosterone and glomerular filtration--observations in the general population |
| Q38525979 | Aldosterone and the Mineralocorticoid Receptor: Risk Factors for Cardiometabolic Disorders |
| Q24194979 | Aldosterone antagonists for preventing the progression of chronic kidney disease |
| Q37772047 | Aldosterone blockade in chronic kidney disease: can it improve outcome? |
| Q42959024 | Aldosterone breakthrough during angiotensin receptor blocker use: more questions than answers? |
| Q36210088 | Aldosterone deficiency and mineralocorticoid receptor antagonism prevent angiotensin II-induced cardiac, renal, and vascular injury. |
| Q36776435 | Aldosterone in vascular and metabolic dysfunction |
| Q27016157 | Aldosterone synthase inhibition in humans |
| Q38590227 | An update of the blockade of the renin angiotensin aldosterone system in clinical practice |
| Q50605578 | Anti-albuminuric effect of the aldosterone blocker eplerenone in non-diabetic hypertensive patients with albuminuria: a double-blind, randomised, placebo-controlled trial. |
| Q36079520 | Anti-albuminuric effects of spironolactone in patients with type 2 diabetic nephropathy: a multicenter, randomized clinical trial |
| Q92536909 | Antifibrotic Roles of RAAS Blockers: Update |
| Q37887401 | Antifibrotic treatment and other new strategies for improving renal outcomes |
| Q26865691 | Antihypertensive treatment and renal protection: the role of drugs inhibiting the renin-angiotensin-aldosterone system |
| Q36026304 | Antioxidants in kidney diseases: the impact of bardoxolone methyl |
| Q49136022 | Approach to cardiovascular disease prevention in patients with chronic kidney disease |
| Q37566950 | Blood pressure control in type 2 diabetic patients |
| Q51659952 | CS-3150, a Novel Nonsteroidal Mineralocorticoid Receptor Antagonist, Shows Preventive and Therapeutic Effects On Renal Injury in Deoxycorticosterone Acetate/Salt-Induced Hypertensive Rats. |
| Q53561964 | Cardiorenal protection during chronic renin-angiotensin-aldosterone system suppression: evidences and caveats. |
| Q38382456 | Cardiovascular actions of mineralocorticoid receptor antagonists in patients with chronic kidney disease: A systematic review and meta-analysis of randomized trials |
| Q87393463 | Chapter 2: Lifestyle and pharmacological treatments for lowering blood pressure in CKD ND patients |
| Q87393470 | Chapter 4: Blood pressure management in CKD ND patients with diabetes mellitus |
| Q30363683 | Clinical therapeutic strategies for early stage of diabetic kidney disease. |
| Q38947325 | Combination of ACE inhibitor with nicorandil provides further protection in chronic kidney disease |
| Q38105019 | Combination use of angiotensin converting enzyme inhibitors and angiotensin receptor blockers in diabetic kidney disease |
| Q34380070 | Comparative effectiveness of renin-angiotensin system blockers and other antihypertensive drugs in patients with diabetes: systematic review and bayesian network meta-analysis |
| Q31143932 | Data and Safety Monitoring Board evaluation and management of a renal adverse event signal in TOPCAT. |
| Q38781550 | Developing Treatments for Chronic Kidney Disease in the 21st Century |
| Q27012546 | Diabetic kidney disease: a report from an ADA Consensus Conference |
| Q27021392 | Diabetic kidney disease: from physiology to therapeutics |
| Q37892915 | Diabetic microvascular complications: possible targets for improved macrovascular outcomes |
| Q28742785 | Diabetic nephropathy - Epidemiology in Asia and the current state of treatment |
| Q43116248 | Diabetic nephropathy: Aldosterone breakthrough in patients on an ACEI. |
| Q86454230 | Diabetic nephropathy: Nonsteroidal MRA added to RAS blockade reduces albuminuria |
| Q36441616 | Diabetic nephropathy: What does the future hold? |
| Q38338539 | Diabetic nephropathy: landmark clinical trials and tribulations |
| Q42951480 | Discovery of Novel Cyanodihydropyridines as Potent Mineralocorticoid Receptor Antagonists |
| Q41450986 | Diverse diuretics regimens differentially enhance the antialbuminuric effect of renin-angiotensin blockers in patients with chronic kidney disease. |
| Q37779518 | Does blockade of the Renin-Angiotensin-aldosterone system slow progression of all forms of kidney disease? |
| Q43962923 | Does hypokalaemia cause nephropathy? An observational study of renal function in patients with Bartter or Gitelman syndrome |
| Q26769787 | Drug Targets for Oxidative Podocyte Injury in Diabetic Nephropathy |
| Q36701736 | Dual Blockade of the Renin-angiotensin-aldosterone System in Type 2 Diabetic Kidney Disease |
| Q37776150 | Dual RAAS blockade is desirable in kidney disease: Con |
| Q38566920 | Dual Renin-Angiotensin-Aldosterone System Inhibition for the Treatment of Diabetic Kidney Disease: Adverse Effects and Unfulfilled Promise |
| Q34604473 | Dual renin-angiotensin-aldosterone system blockade for diabetic kidney disease |
| Q90066163 | Early detection of diabetic kidney disease by urinary proteomics and subsequent intervention with spironolactone to delay progression (PRIORITY): a prospective observational study and embedded randomised placebo-controlled trial |
| Q37156291 | Effect of losartan and spironolactone on triglyceride-rich lipoproteins in diabetic nephropathy |
| Q36127484 | Effect of mineralocorticoid receptor antagonists on proteinuria and progression of chronic kidney disease: a systematic review and meta-analysis |
| Q35546994 | Effective antihypertensive strategies for high-risk patients with diabetic nephropathy |
| Q88727557 | Effects of RAAS Inhibitors in Patients with Kidney Disease |
| Q40965113 | Effects of mineralocorticoid receptor antagonists on the progression of diabetic nephropathy |
| Q36764872 | Efficacy and safety of combined vs. single renin-angiotensin-aldosterone system blockade in chronic kidney disease: a meta-analysis |
| Q93025188 | Efficacy and safety of dosage-escalation of low-dosage esaxerenone added to a RAS inhibitor in hypertensive patients with type 2 diabetes and albuminuria: a single-arm, open-label study |
| Q36567554 | Efficacy and safety of dual blockade of the renin-angiotensin system: meta-analysis of randomised trials |
| Q37806614 | Endothelial dysfunction as a potential contributor in diabetic nephropathy |
| Q35647853 | Epigenetics in diabetic kidney disease |
| Q45741322 | Evaluation of spironolactone plus hydrochlorothiazide in reducing proteinuria in type 2 diabetic nephropathy. |
| Q42683699 | FK506 ameliorates podocyte injury in type 2 diabetic nephropathy by down-regulating TRPC6 and NFAT expression |
| Q38533385 | Finerenone : third-generation mineralocorticoid receptor antagonist for the treatment of heart failure and diabetic kidney disease |
| Q38817871 | Finerenone: a New Mineralocorticoid Receptor Antagonist Without Hyperkalemia: an Opportunity in Patients with CKD? |
| Q53225434 | Fluorofenidone attenuates diabetic nephropathy and kidney fibrosis in db/db mice. |
| Q35028043 | Genetic Predisposition to Diabetic Nephropathy: Evidence for a Role of ACE (I/D) Gene Polymorphism in Type 2 Diabetic Population from Kutch Region |
| Q38800239 | Global cardiovascular protection in chronic kidney disease |
| Q50237155 | Histamine-dependent prolongation by aldosterone of vasoconstriction in isolated small mesenteric arteries of the mouse |
| Q53009256 | Human liver-type fatty acid-binding protein protects against tubulointerstitial injury in aldosterone-induced renal injury. |
| Q35953909 | Hypertension Management in Diabetic Kidney Disease |
| Q37827620 | Hypertension in diabetic nephropathy: epidemiology, mechanisms, and management |
| Q37764468 | Hypertension in the kidney transplant recipient. |
| Q37703801 | I brazilian position paper on antihypertensive drug combination |
| Q36645971 | Implications of treatment that target protective mechanisms against diabetic nephropathy |
| Q28080717 | Improvements in the Management of Diabetic Nephropathy |
| Q45701778 | Incidence, Severity, and Outcomes of AKI Associated with Dual Renin-Angiotensin System Blockade. |
| Q35491275 | Inhibition of RAS in diabetic nephropathy |
| Q27027792 | Is there a new dawn for selective mineralocorticoid receptor antagonism? |
| Q36783886 | Limitations and future treatment options in type 2 diabetes with renal impairment |
| Q61455542 | Long-term blockade of the renin–angiotensin system: an adequate evaluation is still needed |
| Q30413119 | Long-term effects of spironolactone in peritoneal dialysis patients |
| Q30353386 | Management of Diabetic Nephropathy in the Elderly: Special Considerations. |
| Q37869806 | Management of blood pressure in patients with diabetes |
| Q38052452 | Management of hyperkalaemia consequent to mineralocorticoid-receptor antagonist therapy |
| Q102211197 | Management of hyperkalemia during treatment with mineralocorticoid receptor blockers: findings from esaxerenone |
| Q95327029 | Management of primary aldosteronism and mineralocorticoid receptor-associated hypertension |
| Q90470119 | Microalbuminuria and cardiorenal risk: old and new evidence in different populations |
| Q33734806 | Mineralocorticoid Receptor Signaling as a Therapeutic Target for Renal and Cardiac Fibrosis. |
| Q38119861 | Mineralocorticoid receptor activation as an etiological factor in kidney diseases |
| Q37998573 | Mineralocorticoid receptor antagonist for renal protection |
| Q34168923 | Mineralocorticoid receptor antagonists and the metabolic syndrome |
| Q26864370 | Mineralocorticoid receptor blockade in chronic kidney disease |
| Q37861583 | Mineralocorticoid receptor blockade in chronic kidney disease |
| Q90989973 | Mineralocorticoid receptor blockade suppresses dietary salt-induced ACEI/ARB-resistant albuminuria in non-diabetic hypertension: a sub-analysis of evaluate study |
| Q37976974 | Mineralocorticoid receptor-associated hypertension and its organ damage: clinical relevance for resistant hypertension |
| Q34071671 | Moderate antiproteinuric effect of add-on aldosterone blockade with eplerenone in non-diabetic chronic kidney disease. A randomized cross-over study |
| Q37899907 | New approaches to the treatment of nephropathy in diabetes |
| Q35125585 | New insight into the molecular drug target of diabetic nephropathy |
| Q38265818 | Novel effective drugs for diabetic kidney disease? or not? |
| Q99564962 | Nuclear receptors in podocyte biology and glomerular disease |
| Q37601245 | Obesity, hypertension, and chronic kidney disease |
| Q37812022 | Pathogenesis and therapeutic implications of cardiorenal syndrome |
| Q90317854 | Pathophysiological mechanisms of mineralocorticoid receptor-dependent cardiovascular and chronic kidney disease |
| Q37553108 | Potassium handling with dual renin-angiotensin system inhibition in diabetic nephropathy |
| Q26864133 | Present and future in the treatment of diabetic kidney disease |
| Q90666788 | Prognostic Value of Albuminuria and Influence of Spironolactone in Heart Failure With Preserved Ejection Fraction |
| Q35967679 | Proteinuria in dogs and cats |
| Q37964266 | Proteinuria: detection and role in native renal disease progression |
| Q35557410 | Quantifying the effects of diuretics and β-adrenoceptor blockers on glycaemic control in diabetes mellitus - a systematic review and meta-analysis. |
| Q83802294 | RAS blockade, hyperkalemia and AKI--look and you will find |
| Q54978317 | Rapeseed protein-derived antioxidant peptide RAP alleviates renal fibrosis through MAPK/NF-κB signaling pathways in diabetic nephropathy. |
| Q48131156 | Recent Insights into Pharmacologic Cardiovascular Risk Reduction in Type 2 Diabetes Mellitus |
| Q26745900 | Recent advances in managing and understanding diabetic nephropathy |
| Q93609101 | References |
| Q36329456 | Renin-Angiotensin-Aldosterone System Blockade in Diabetic Nephropathy. Present Evidences |
| Q37959062 | Renin-angiotensin system blockade and reduction of cardiovascular risk: future perspectives |
| Q38777543 | Renin-angiotensin-aldosterone system blockade in chronic kidney disease: current strategies and a look ahead |
| Q46819030 | Renin-angiotensin-aldosterone system genotypes and haplotypes affect the susceptibility to nephropathy in type 2 diabetes patients |
| Q42624224 | Serum potassium in dual renin-angiotensin-aldosterone system blockade |
| Q64228363 | Spironolactone alleviates diabetic nephropathy through promoting autophagy in podocytes |
| Q39460266 | Spironolactone improves nephropathy by enhancing glucose-6-phosphate dehydrogenase activity and reducing oxidative stress in diabetic hypertensive rat. |
| Q39809455 | Spironolactone promotes autophagy via inhibiting PI3K/AKT/mTOR signalling pathway and reduce adhesive capacity damage in podocytes under mechanical stress |
| Q34450762 | Spironolactone rescues Dot1a-Af9-mediated repression of endothelin-1 and improves kidney injury in streptozotocin-induced diabetic rats |
| Q39038196 | THE IMPACT OF CARDIOVASCULAR DRUGS ON GLYCEMIC CONTROL: A REVIEW |
| Q93169634 | The Ascent of Mineralocorticoid Receptor Antagonists in Diabetic Nephropathy |
| Q63681844 | The Long-Term Impact of Renin-Angiotensin System (RAS) Inhibition on Cardiorenal Outcomes (LIRICO): A Randomized, Controlled Trial |
| Q37741783 | The RAAS in the pathogenesis and treatment of diabetic nephropathy |
| Q48025446 | The Role of the Mineralocorticoid Receptor in Inflammation: Focus on Kidney and Vasculature. |
| Q35883217 | The central mechanism underlying hypertension: a review of the roles of sodium ions, epithelial sodium channels, the renin-angiotensin-aldosterone system, oxidative stress and endogenous digitalis in the brain |
| Q37828061 | The contribution of hypertension to diabetic nephropathy and retinopathy: the role of inflammation and oxidative stress |
| Q38168046 | The effect of RAAS blockade on the progression of diabetic nephropathy |
| Q64092005 | The endogenous cardiotonic steroid Marinobufagenin and decline in estimated glomerular filtration rate at follow-up in patients with arterial hypertension |
| Q33632021 | The impact of antihypertensives on kidney disease |
| Q35760302 | The kidney in type 2 diabetes therapy |
| Q38374536 | The necessity and effectiveness of mineralocorticoid receptor antagonist in the treatment of diabetic nephropathy |
| Q38249107 | The role of aldosterone antagonism agents in diabetic kidney disease |
| Q35834925 | The use of plasma aldosterone and urinary sodium to potassium ratio as translatable quantitative biomarkers of mineralocorticoid receptor antagonism |
| Q27007027 | Therapeutic modalities in diabetic nephropathy: standard and emerging approaches. |
| Q37939427 | Therapeutic perspectives in hypertension: novel means for renin-angiotensin-aldosterone system modulation and emerging device-based approaches |
| Q26996385 | Therapeutic targeting of aldosterone: a novel approach to the treatment of glomerular disease |
| Q38236013 | Treating hypertension in type 2 diabetes |
| Q27694623 | Treatment of chronic kidney disease |
| Q36100123 | Understanding the mechanisms of proteinuria: therapeutic implications |
| Q37803235 | Which antihypertensive drugs are the most nephroprotective and why? |
Search more.